Showing results (61-70 of 154) with videos related to

Sort By:
Pageof 16
Journal of Acquired Immune Deficiency Syndromes (1999)|June 29, 2013
Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adultsPeter J Ruane, Edwin DeJesus, Daniel Berger, et al.
Plos One|May 15, 2014
Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trialDavid A Wohl, Laveeza Bhatti, Catherine B Small, et al.
AIDS (London, England)|July 2, 2014
Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findingsDavid A Cooper, Jayvant Heera, Prudence Ive, et al.
AIDS (London, England)|January 28, 2006
Pharmacokinetics, pharmacodynamics and safety of once-daily versus twice-daily dosing with enfuvirtide in HIV-infected subjectsMelanie Thompson, Edwin DeJesus, Gary Richmond, et al.
HIV Clinical Trials|October 23, 2013
Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimensAnthony M Mills, Calvin Cohen, Edwin Dejesus, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 23, 2013
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 resultsJürgen K Rockstroh, Edwin DeJesus, Keith Henry, et al.
HIV Clinical Trials|May 31, 2017
Simplification to single-tablet regimen of elvitegravir, cobicistat, emtricitabine, tenofovir DF from multi-tablet ritonavir-boosted protease inhibitor plus coformulated emtricitabine and tenofovir DF regimens: week 96 results of STRATEGY-PIJose R Arribas, Edwin DeJesus, Jan van Lunzen, et al.
AIDS Research and Human Retroviruses|March 27, 2009
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758Charles B Hicks, Edwin DeJesus, Louis M Sloan, et al.
Lancet (London, England)|July 4, 2012
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trialEdwin DeJesus, Jürgen K Rockstroh, Keith Henry, et al.
The Journal of Infectious Diseases|January 15, 2004
Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1Daniel R Kuritzkes, Jeffrey Jacobson, William G Powderly, et al.
Pageof 16